Following its review of cough and cold medication use in children, the Irish Medicines Board (IMB) no longer advises their use in children under six years of age.
The decision comes soon after a similar conclusion was reached by the FDA in America. In it's letter to healthcare professionals the IMB states that: "These recommendations reflect an evolution in the therapeutic strategy over time for the management of coughs and colds in children rather than the emergence of any new safety concern."
Non-prescription cough and cold medicines containing the following active ingredients are affected by the new recommendations:
Antitussives: dextromethorphan and pholcodine*
Expectorants: guaifenesin and ipecacuanha
Nasal decongestants: oxymetazoline, phenylephrine, pseudoephedrine and xylometazoline
Antihistamines: brompheniramine, diphenhydramine, doxylamine and triprolidine
*Pholcodine containing products are currently subject to an ED review on the benefits and risks of these products. The outcome will be communicated once available. The above recommendations apply to pholcodine containing products in the interim pending any further changes.
As coughs and colds occur quiet frequently in children and are generally self-limiting, there is little evidence of efficacy of cough and cold medicines containing the above ingredients. "Given that there have been some reports of harm globally with these ingredients, the risks of cough and cold medicines containing them are now considered to outweigh their benefits in children less than 6 years.", conclude the IMB.
Over the Counter (OTC) cough and cold products which are no longer recommended for use in children under 6 years are listed below:
Post new comment